Hepatitis B Virus Reactivation with a Rituximab-containing Regimen

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Sep 29

PMID 26413224

Citations 30

Authors

Yutaka Tsutsumi

Yoshiya Yamamoto

Shinichi Ito

Hiroyuki Ohigashi

Souichi Shiratori

Hirohito Naruse

Takanori Teshima

Affiliations

Soon will be listed here.

Abstract

Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transplants. Due to rituximab's widespread use, great progress has been made regarding research into complications that arise from its use, one of the most serious being the reactivation of hepatitis B virus (HBV), and efforts continue to establish guidelines for preventive treatment against this occurrence. This report discusses preventive measures against rituximab-induced HBV reactivation and future objectives.

Citing Articles

Cancer-Chemotherapy-Related Regimen Checks Performed by Pharmacists of General Hospitals Other than Cancer Treatment Collaborative Base Hospitals: A Multicenter, Prospective Survey.

Ueki D, Suzuki S, Ohta T, Shinohara A, Ohashi Y, Konuma D Pharmacy (Basel). 2024; 12(1).

PMID: 38392922 PMC: 10891652. DOI: 10.3390/pharmacy12010001.

Hepatitis B Virus Reactivation with Immunosuppression: A Hidden Threat?.

Anvari S, Tsoi K J Clin Med. 2024; 13(2).

PMID: 38256527 PMC: 10816226. DOI: 10.3390/jcm13020393.

Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs.

Prosty C, Katergi K, Nguyen A, Luo O, Sorin M, Cherniak V Blood Adv. 2023; 8(4):857-866.

PMID: 38154071 PMC: 10875332. DOI: 10.1182/bloodadvances.2023011964.

Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature.

Mazzaro C, Bomben R, Visentini M, Gragnani L, Quartuccio L, Saccardo F Front Oncol. 2023; 13:1095780.

PMID: 36824142 PMC: 9941626. DOI: 10.3389/fonc.2023.1095780.

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.

Ly S, Nedosekin D, Wong H Am J Clin Dermatol. 2023; 24(2):247-273.

PMID: 36630066 PMC: 9838371. DOI: 10.1007/s40257-022-00751-7.

References

Maloney D, Liles T, Czerwinski D, Waldichuk C, Rosenberg J, Grillo-Lopez A . Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994; 84(8):2457-66. View

Maloney D, Grillo-Lopez A, Bodkin D, White C, Liles T, Royston I . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997; 15(10):3266-74. DOI: 10.1200/JCO.1997.15.10.3266. View

Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F . Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997; 8 Suppl 1:107-9. View

Jaeger G, Neumeister P, Brezinschek R, Hofler G, Quehenberger F, Linkesch W . Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol. 2002; 69(1):21-6. DOI: 10.1034/j.1600-0609.2002.01692.x. View

Lok A, Liang R, Chiu E, Wong K, Chan T, Todd D . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100(1):182-8. DOI: 10.1016/0016-5085(91)90599-g. View

Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J . Rituximab administration and reactivation of HBV. Hepat Res Treat. 2010; 2010:182067. PMC: 3003947. DOI: 10.1155/2010/182067. View

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2007; 45(2):507-39. DOI: 10.1002/hep.21513. View

Yeo W, Zee B, Zhong S, Chan P, Wong W, Ho W . Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90(7):1306-11. PMC: 2409681. DOI: 10.1038/sj.bjc.6601699. View

Dai M, Chao T, Kao W, Shyu R, Liu T . Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004; 83(12):769-74. DOI: 10.1007/s00277-004-0899-y. View

10.

Ji D, Cao J, Hong X, Li J, Wang J, Chen F . Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010; 85(3):243-50. DOI: 10.1111/j.1600-0609.2010.01474.x. View

11.

Zurawska U, Hicks L, Woo G, Bell C, Krahn M, Chan K . Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol. 2012; 30(26):3167-73. DOI: 10.1200/JCO.2011.40.7510. View

12.

Salpini R, Colagrossi L, Bellocchi M, Surdo M, Becker C, Alteri C . Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2014; 61(3):823-33. DOI: 10.1002/hep.27604. View

13.

Skrabs C, Muller C, Agis H, Mannhalter C, Jager U . Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia. 2002; 16(9):1884-6. DOI: 10.1038/sj.leu.2402567. View

14.

Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B . Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica. 2003; 88(11):1296-303. View

15.

Peters M, Hann Hw H, Martin P, Heathcote E, Buggisch P, Rubin R . Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2003; 126(1):91-101. DOI: 10.1053/j.gastro.2003.10.051. View

16.

. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2008; 50(2):227-42. DOI: 10.1016/j.jhep.2008.10.001. View

17.

Win L, Powis J, Shah H, Feld J, Wong D . Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations. Case Reports Hepatol. 2014; 2013:454897. PMC: 4208428. DOI: 10.1155/2013/454897. View

18.

Webster G, Reignat S, Maini M, Whalley S, Ogg G, King A . Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000; 32(5):1117-24. DOI: 10.1053/jhep.2000.19324. View

19.

Seto W, Chan T, Hwang Y, Wong D, Fung J, Liu K . Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014; 32(33):3736-43. DOI: 10.1200/JCO.2014.56.7081. View

20.

Liaw Y, Leung N, Guan R, Lau G, Merican I, McCaughan G . Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005; 25(3):472-89. DOI: 10.1111/j.1478-3231.2005.01134.x. View